Hans-Peter Rihs

Dr. Hans-Peter Rihs

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
IDIne Ilona Decuyper
Ine Ilona Decuyper
AGAthina Ludovica Van Gasse
Athina Ludovica Van Gasse
MFMargaretha A. Faber
Margaretha A. Faber
JEJessy Elst
Jessy Elst
CMChristel Mertens
Christel Mertens
DEDidier Gaston Ebo
Didier Gaston Ebo

1 May 2017 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
IDIne I. Decuyper
Ine I. Decuyper
MFMargaretha A. Faber
Margaretha A. Faber
VSVito Sabato
Vito Sabato
CBChris H. Bridts
Chris H. Bridts
MHMargo M. Hagendorens
Margo M. Hagendorens
DEDidier G. Ebo
Didier G. Ebo

4 April 2019 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
IDIne Ilona Decuyper
Ine Ilona Decuyper
HRHans-Peter Rihs
Hans-Peter Rihs
AGAthina Ludovica Van Gasse
Athina Ludovica Van Gasse
JEJessy Elst
Jessy Elst
LPLeander De Puysseleyr
Leander De Puysseleyr
DEDidier Gaston Ebo
Didier Gaston Ebo
Introduction: Although the use of cannabis dates back millennia, the first description of cannabis allergy is relatively recent (1971). Recent large-scale data show that cannabis allergy can manifest severe and generalized symptoms with extensive cross-reactions. Thus, it is essential to become familiarized with its clinical presentation, diagnostic aids, and adequate therapeutic guidance. Areas covered: Here we provide a hands-on overview on cannabis allergy focusing on symptomatology and the reliability of diagnostic options. Recent advances in proteomics are discussed in detail, elucidating the link with nsLTP-related allergies. The proteomics advancements have paved the way for more reliable diagnostics, especially component-based tools. Finally, the current experience in treatment options is highlighted. Expert opinion: Cannabis allergy is an allergy entity which can significantly impact the quality of life. For optimal diagnosis, we advise to start with a validated and standardized crude-extract based test such as sIgE hemp complemented by component-based diagnostics such as sIgE Can s 3 quantifications where available. Future research should lift the veil on the true prevalence of cannabis allergy and the importance of other cannabis allergens to further guide our practice.

30 May 2018 in Allergy
Verified
Journal Article
Closed access
PDF file
IDI. I. Decuyper
I. I. Decuyper
MFM. A. Faber
M. A. Faber
HLH. Lapeere
H. Lapeere
CMC. Mertens
C. Mertens
HRHans-Peter Rihs
Hans-Peter Rihs
DED. G. Ebo
D. G. Ebo

15 December 2018 in Occupational and Environmental Medicine
Verified
Journal Article
Closed access
PDF file
IDIne Ilona Decuyper
Ine Ilona Decuyper
AGAthina Van Gasse
Athina Van Gasse
MFMargaretha Antje Faber
Margaretha Antje Faber
CMChristel Mertens
Christel Mertens
JEJessy Elst
Jessy Elst
DEDidier Ebo
Didier Ebo
Objectives Cannabis allergy has mainly been described following recreational use but some cases also point to cannabis sensitisation as a result of occupational exposure. As a consequence, little is known on the prevalence and clinical phenotype of occupational cannabis allergy. Therefore, this study aims to explore the allergy-associated health risks of occupational cannabis exposure in Belgian police force personnel. Methods 81 participants, active in the police force, reporting regular occupational cannabis exposure during the past 12 months, were included. History was combined with a standardised questionnaire on allergies and cannabis exposure.Basophil activation tests (BATs) with a crude cannabis extract and rCan s 3 were performed. In addition, specific (s)IgE rCan s 3 as well as sIgE to house dust mite, six pollen and three mould allergens were quantified. Results Although 42% of the participants reported respiratory and/or cutaneous symptoms on occupational cannabis exposure, all cannabis diagnostics were entirely negative, except one symptomatic case demonstrating a borderline result. Furthermore, there is no significant difference between the groups with and without symptoms on cannabis exposure in terms of allergenic sensitisations. Conclusions The origins of the reported respiratory and cutaneous symptoms during cannabis exposure remain elusive but are probably due to non-immune reactions. It should be noted that the study was volunteer-based possibly reflecting an excessive number of symptomatic individuals. Nevertheless, as only one participant reported using fully protective gear, much improvement is needed for reducing the number of symptoms reported on duty, independent of their origin.

24 February 2020 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
DEDidier G. Ebo
Didier G. Ebo
CBChris H. Bridts
Chris H. Bridts
HRHans-Peter Rihs
Hans-Peter Rihs
Introduction: IgE-mediated Hevea latex allergy and associated food-allergies constitute a significant health issue with serious consequences of diagnostic error. Hence, there is need for more reliable confirmatory diagnostics. Areas covered: Here, we summarize the major limitations of conventional tests using native extracts and describe how piecing together the IgE reactivity profile can benefit correct diagnosis in difficult cases in whom conventional tests yield equivocal or negative results. A diagnostic algorithm integrating traditional sIgE and component resolved diagnosis (CRD) is presented. Expert opinion: Moreover, it is clear that the discoveries in the field of the Hevea latex proteome will contribute to our understandings and accurate approach of sometimes complex cross-reactivity phenomena that extend beyond the “latex-fruit syndrome”.